Immuneering Reports Third Quarter 2023 Financial Results and Provides Business Updates
09 nov. 2023 16h05 HE
|
Immuneering Corporation
-Dose evaluation portion of IMM-1-104 Phase 1/2a trial approximately two-thirds enrolled; Immuneering’s recommendation for a Phase 2 dose expected in early 2024 - - Expanded clinical development...
Non-Invasive Cancer Diagnostics Market Size & Share Surpass USD 207 billion by 2031, Growing at a CAGR of 7.0% - Exclusive Study by Transparency Market Research
19 oct. 2023 11h30 HE
|
Transparency Market Research
Wilmington, Delaware, United States, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. -The global non-invasive cancer diagnostics market is projected to flourish at a CAGR of 7.0%...
Noah Medical’s Galaxy System™ Named Finalist in 2023 Fierce Innovation Awards
19 oct. 2023 08h00 HE
|
Noah Medical
Medical robotics innovator Noah Medical announced today that its Galaxy System was named a finalist in the 2023 Fierce Innovation Awards.
Global Targeted Therapeutics Market Size to Reach USD 214.31 Billion in 2032 | Emergen Research
16 oct. 2023 09h09 HE
|
Emergen Research
Vancouver, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Current Market Scenario (Market estimates) The global Targeted Therapeutics Market size was USD 93.75 Billion in 2020. Increasing prevalence of cancer,...
Immuneering Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC Conference
12 oct. 2023 16h05 HE
|
Immuneering Corporation
– Expanded benchmarking of IMM-1-104 as a single agent across more than 190 patient-aligned models in humanized 3D-tumor growth assays demonstrated high sensitivity in a wide range of MAPK-driven...
Machine Learning Model Unveils Stunning Lung Cancer Risk Predictions
05 oct. 2023 11h58 HE
|
Research and Markets
Dublin, Oct. 05, 2023 (GLOBE NEWSWIRE) -- In a recent groundbreaking study published on October 3rd in the open access journal PLOS Medicine, Thomas Callender of University College London and his...
Ocean Biomedical Announces Non-Dilutive Amendment to Existing Agreement with a Key Financing Partner
03 oct. 2023 14h30 HE
|
Ocean Biomedical, Inc.
Providence, RI, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA) announced today that the company and Polar Multi-Strategy Master Fund (Polar), a significant long-time...
Targeted Therapeutics Market Size & Share to Surpass $80.9 Billion by 2030 | Vantage Market Research
19 sept. 2023 09h13 HE
|
Vantage Market Research
WASHINGTON, Sept. 19, 2023 (GLOBE NEWSWIRE) -- As per Vantage Market Research, the Global Targeted Therapeutics Market has been steadily growing over the years due to the increasing prevalence of...
Global Lung Cancer Screening Market Size and Forecast to 2030: The Cost Conundrum - Challenges Posed by High Lung Cancer Screening Test Expenses
19 sept. 2023 08h48 HE
|
Research and Markets
Dublin, Sept. 19, 2023 (GLOBE NEWSWIRE) -- The "Lung Cancer Screening Market Size and Forecast to 2030 - Global Analysis by Cancer Type [Non-Small Cell Lung Cancer and Small Cell Lung Cancer],...
Burning Rock's minimal residual disease (MRD) product supports advancement in early-stage non-small cell lung cancer treatment, with results published in the Cancer Cell
07 sept. 2023 22h43 HE
|
Burning Rock Biotech Limited
GUANGZHOU, China, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”) is delighted to announce that our personalized Minimal...